|
Name |
Peaurantiogriseol F
|
| Molecular Formula | C16H26O4 | |
| IUPAC Name* |
1-[(1S,2R,4aS,6R,8aS)-2-hydroxy-6-(hydroxymethyl)-1,2-dimethyl-4a,5,6,7,8,8a-hexahydronaphthalen-1-yl]-3-hydroxypropan-1-one
|
|
| SMILES |
C[C@]1(C=C[C@@H]2C[C@@H](CC[C@@H]2[C@]1(C)C(=O)CCO)CO)O
|
|
| InChI |
InChI=1S/C16H26O4/c1-15(20)7-5-12-9-11(10-18)3-4-13(12)16(15,2)14(19)6-8-17/h5,7,11-13,17-18,20H,3-4,6,8-10H2,1-2H3/t11-,12-,13+,15-,16-/m1/s1
|
|
| InChIKey |
OUZGQMNHNDSUKM-CNRIWFPOSA-N
|
|
| Synonyms |
Peaurantiogriseol F; CHEBI:189141; 1-[(1S,2R,4aS,6R,8aS)-2-hydroxy-6-(hydroxymethyl)-1,2-dimethyl-4a,5,6,7,8,8a-hexahydronaphthalen-1-yl]-3-hydroxypropan-1-one
|
|
| CAS | NA | |
| PubChem CID | 139583908 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 282.37 | ALogp: | 1.0 |
| HBD: | 3 | HBA: | 4 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 77.8 | Aromatic Rings: | 2 |
| Heavy Atoms: | 20 | QED Weighted: | 0.687 |
| Caco-2 Permeability: | -4.67 | MDCK Permeability: | 0.00001810 |
| Pgp-inhibitor: | 0.026 | Pgp-substrate: | 0.611 |
| Human Intestinal Absorption (HIA): | 0.05 | 20% Bioavailability (F20%): | 0.005 |
| 30% Bioavailability (F30%): | 0.005 |
| Blood-Brain-Barrier Penetration (BBB): | 0.936 | Plasma Protein Binding (PPB): | 14.15% |
| Volume Distribution (VD): | 0.627 | Fu: | 57.02% |
| CYP1A2-inhibitor: | 0.02 | CYP1A2-substrate: | 0.82 |
| CYP2C19-inhibitor: | 0.022 | CYP2C19-substrate: | 0.795 |
| CYP2C9-inhibitor: | 0.012 | CYP2C9-substrate: | 0.112 |
| CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.041 |
| CYP3A4-inhibitor: | 0.467 | CYP3A4-substrate: | 0.522 |
| Clearance (CL): | 6.409 | Half-life (T1/2): | 0.896 |
| hERG Blockers: | 0.017 | Human Hepatotoxicity (H-HT): | 0.37 |
| Drug-inuced Liver Injury (DILI): | 0.057 | AMES Toxicity: | 0.078 |
| Rat Oral Acute Toxicity: | 0.104 | Maximum Recommended Daily Dose: | 0.16 |
| Skin Sensitization: | 0.756 | Carcinogencity: | 0.872 |
| Eye Corrosion: | 0.22 | Eye Irritation: | 0.856 |
| Respiratory Toxicity: | 0.909 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001954 | ![]() |
0.750 | D0D1SG | ![]() |
0.289 | ||
| ENC003792 | ![]() |
0.631 | D0V9DZ | ![]() |
0.283 | ||
| ENC003690 | ![]() |
0.621 | D08PIQ | ![]() |
0.283 | ||
| ENC005218 | ![]() |
0.597 | D0IT2G | ![]() |
0.277 | ||
| ENC003798 | ![]() |
0.466 | D0CW1P | ![]() |
0.277 | ||
| ENC003775 | ![]() |
0.438 | D03BLF | ![]() |
0.277 | ||
| ENC003781 | ![]() |
0.382 | D07DVK | ![]() |
0.277 | ||
| ENC002228 | ![]() |
0.292 | D0IL7L | ![]() |
0.276 | ||
| ENC003119 | ![]() |
0.287 | D0I5DS | ![]() |
0.270 | ||
| ENC005787 | ![]() |
0.273 | D03IKT | ![]() |
0.265 | ||